India’s pharma industry betting big on CDMO opportunity – All you need to know

India’s CDMO market is experiencing robust growth due to cost advantages, technology advancements, and a supportive regulatory framework. It is expected to reach $465.14 billion by 2032, with India becoming a preferred outsourcing destination for pharmaceutical manufacturing. The government’s proactive support and incentives have further boosted the industry.